Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Notification Letter with Request Form to Non-Registered Shareholders
Regulatory Filings Classification · 95% confidence The document is a letter dated 16 January 2024 from Lepu Biopharma Co., Ltd. addressed to non-registered shareholders. It informs them about the company's adoption of electronic dissemination of corporate communications pursuant to the Listing Rules of the Hong Kong Stock Exchange. The letter explains what constitutes corporate communications, including annual reports, interim reports, notices of meetings, circulars, and proxy forms. It also provides instructions for shareholders on how to receive these communications electronically or in printed form. The document includes a reply form for shareholders to request printed copies. There are no financial statements, management discussion, audit reports, or earnings data included. The document is essentially an announcement about the method of distribution of corporate communications rather than the communications themselves or any financial report. It is a regulatory compliance communication related to shareholder communication methods and does not fit into categories like Annual Report, Interim Report, or Earnings Release. Given its nature as a formal notification about corporate communication dissemination and shareholder instructions, it best fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-01-16 English
Notification Letter with Request Form to Registered Shareholders
Regulatory Filings Classification · 95% confidence The document is a letter dated 16 January 2024 from Lepu Biopharma Co., Ltd. addressed to registered shareholders. It informs shareholders about the company's adoption of electronic dissemination of corporate communications pursuant to a new rule (Rule 2.07A) under the Hong Kong Stock Exchange Listing Rules effective 31 December 2023. The letter explains the types of corporate communications covered, including annual reports, interim reports, notices of meetings, circulars, and proxy forms. It solicits shareholders to provide email addresses to receive these communications electronically and offers options for receiving printed copies. The document includes a reply form for shareholders to respond. There are no financial statements, management discussion, audit opinions, or earnings data present. The document is an announcement about the method of distributing corporate communications rather than the communications themselves or any financial report. It is also longer than 5,000 characters but does not contain substantive financial data or report content. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about corporate communication dissemination and shareholder instructions, not a report or financial filing itself.
2024-01-16 English
CLOSURE OF REGISTER OF MEMBERS FOR THE 2024 FIRST AND SECOND EXTRAORDINARY GENERAL MEETINGS TO BE HELD ON JANUARY 31, 2024
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the closure of the register of members for upcoming extraordinary general meetings (EGMs) scheduled on January 31, 2024. It references previous announcements and details the administrative arrangements for shareholder eligibility to attend and vote at these meetings. The document does not contain financial statements, detailed financial data, or the actual meeting materials but rather logistical information about shareholder registration and meeting dates. It also mentions that circulars with details of resolutions and proxy forms will be sent later, indicating this is a preparatory announcement rather than the meeting materials themselves. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement related to shareholder meeting arrangements and does not fall into more specific categories like AGM Information or Declaration of Voting Results.
2024-01-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities for Lepu Biopharma Co., Ltd. It includes information on authorised/registered share capital, issued shares, and confirmations related to securities issued during the month ended 31 December 2023. The document is submitted to the Hong Kong Exchanges and Clearing Limited and follows the format FF301, which is a regulatory return related to share capital and securities movements. It does not contain financial statements, earnings data, or management discussion. It is a regulatory compliance filing reporting share capital and securities movements rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-04 English
VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT OF PIVOTAL PHASE IIb CLINICAL TRIAL FOR MRG003 FOR THE TREATMENT OF R/M NPC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Lepu Biopharma Co., Ltd. regarding the completion of patient enrollment in a pivotal Phase IIb clinical trial for their drug candidate MRG003. It provides information about the clinical trial progress, drug details, regulatory designations, and a cautionary note to investors. The document is relatively short (3853 characters) and does not contain financial statements, detailed financial analysis, or regulatory certifications. It is an announcement of a clinical trial milestone rather than a financial report, management change, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not related to capital changes, voting results, or legal proceedings. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-12-28 English
ANNOUNCEMENT IN RELATION TO THE CONTINUING CONNECTED TRANSACTION THE SUPPLEMENTAL CDMO SERVICES FRAMEWORK AGREEMENT AND THE PROPOSED REVISED CAP
Regulatory Filings Classification · 95% confidence The document is an announcement by Lepu Biopharma Co., Ltd. regarding a supplemental agreement to a continuing connected transaction framework agreement and a proposed revised cap. It discusses the background, terms, and regulatory implications of the transaction, including the need for shareholder approval at an extraordinary general meeting (EGM). The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about a corporate transaction and related shareholder meeting arrangements. It does not contain financial statements or detailed financial analysis but focuses on the transaction terms, regulatory compliance, and meeting arrangements. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-12-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.